Pharmaceutical Industry in Vietnam: Sluggish Sector in a Growing Market

Angelino, Antonio; Khánh, Đỗ Tá; Ha, Nguyen An; Anh, Tuan Pham

doi:10.3390/ijerph14090976

Cited by 30 publications

(30 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ageing trends and increased income in the so-called emerging countries have effects on both the global demand of medicines and on the organization of the supply of such goods [ 73 , 103 ]. Studying a country like China, given its important weight both in terms of population and manufacturing capacity, is crucial to better understanding such changes.…”

Section: Discussionmentioning

confidence: 99%

Restructuring the Production of Medicines: An Investigation on the Pharmaceutical Sector in China and the Role of Mergers and Acquisitions

Barbieri

Huang

Pi³

et al. 2017

IJERPH

View full text Add to dashboard Cite

In places like China, an ageing population coupled with changes in living standards and increases in disposable income, imply a shift of the demand for health-related goods and services which is likely to affect the whole organization of the industries that supply such goods and services at the global level. One of the industries most likely to be affected is the pharmaceutical sector. In the early 2000s China was already the second largest global producer of pharmaceutical ingredients. The pharmaceutical sector has become one of the most important industries promoted by the Chinese government and Five-Year Plan of China’s Strategic Emerging Sectors, mergers and acquisition (M&A) activity has been the key strategy to restructure the sector and increase its competitiveness. This paper firstly provides an updated picture of the evolution of M&As in the pharmaceutical sector, compared to other sectors, in China in the period 2005–2013. Secondly, we develop a composite indicator to measure the industrial performance of all Chinese industrial sectors over time, which allows us to assess the performance of the pharmaceutical industry compared to that of other sectors of the Chinese economy. Finally, we develop and estimate an empirical model that tests the relationship between the number of M&A in a sector and its performance, with a particular focus on the pharmaceutical case. The results offer some initial evidence of positive effects from the process of restructuring of the pharmaceutical sector in China.

show abstract

Section: Discussionmentioning

confidence: 99%

Restructuring the Production of Medicines: An Investigation on the Pharmaceutical Sector in China and the Role of Mergers and Acquisitions

Barbieri

Huang

Pi³

et al. 2017

IJERPH

View full text Add to dashboard Cite

show abstract

“…Vietnam is one of the major growth centres in Asia for the pharmaceutical industry and this growth is expected to continue over the next 20 years [3]. The country has undergone major policy shifts and economic reforms, including a number of radical changes in the pharmaceutical sector and the introduction of laws and regulations from the government to adapt to this growth (Table 1).…”

Section: Introductionmentioning

confidence: 99%

“I can make more from selling medicine when breaking the rules” – understanding the antibiotic supply network in a rural community in Viet Nam

Nguyen

et al. 2019

BMC Public Health

View full text Add to dashboard Cite

BackgroundAs in many other low and middle income countries (LIMCs), Vietnam has experienced a major growth in the pharmaceutical industry, with large numbers of pharmacies and drug stores, and increasing drug expenditure per capita over the past decade. Despite regulatory frameworks that have been introduced to control the dispensing and use of prescription-only drugs, including antibiotics, compliance has been reported to be strikingly low particularly in rural parts of Vietnam. This qualitative study aimed to understand antibiotic access and use practices in the community from both supplier and consumer perspectives in order to support the identification and development of future interventions.MethodsThis qualitative study was part of a project on community antibiotic access and use (ABACUS) in six LMICs. The focus was Ba Vi district of Hanoi capital city, where we conducted 16 indepth interviews (IDIs) with drug suppliers, and 16 IDIs and 6 focus group discussions (FGDs) with community members. Drug suppliers were sampled based on mapping of all informal and formal antibiotic purchase or dispensing points in the study area. Community members were identified through local networks and relationships with the field collaborators. All IDIs and FGDs were audio-taped, transcribed and analysed using content analysis.ResultsWe identified a large number of antibiotic suppliers in the locality with widespread infringements of regulatory requirements. Established reciprocal relationships between suppliers and consumers in drug transactions were noted, as was the consumers’ trust in the knowledge and services provided by the suppliers. In addition, antibiotic use has become a habitual choice in most illness conditions, driven by both suppliers and consumers.ConclusionsThis study presents an analysis of the practices of antibiotic access and use in a rural Vietnamese setting. It highlights the interactions between antibiotic suppliers and consumers in the community and identifies possible targets for interventions.

show abstract

“…To keep medicine prices competitive, the government may consider providing incentives to local manufacturers. For instance, in Vietnam, a national policy prioritising the purchase of domestically produced medicines has been imposed [27]. Other approaches include reducing corporate tax rates, providing soft loans, creating an investment-friendly environment, and increasing infrastructure development [28].…”

Section: Discussionmentioning

confidence: 99%

Association between medicine Price declaration by pharmaceutical industries and retail prices in Malaysia’s private healthcare sector

Ahmad

Hatah

Makmor‐Bakry

2019

J of Pharm Policy and Pract

View full text Add to dashboard Cite

Background As part of the initiatives to increase price transparency for consumers, pharmaceutical industry in Malaysia have been encouraged to declare the wholesale and recommended retail prices (RRP) of medicines to the Pharmaceutical Service Department (PSD) yearly. However, the relationship between the voluntary price reporting practices and consumers’ retail medicine price is unknown. Therefore, this study aims to evaluate the effect of the voluntary price reporting practice of pharmaceutical industry on retail medicine prices, factors that may affect consumer medicine prices in Malaysia’s private healthcare sector, and the retail medicine pricing trend over 2011–2015. Methods A yearly correlation test for a 5-year period was performed to investigate the association between the wholesale and RRP medicine prices declared by the pharmaceutical industry from 2011 to 2015 on the one hand and the consumer wholesale and retail medicine price database on the other hand. The median price ratio (MPR) was calculated by comparing the consumer retail medicine price to its international reference price. The Krukal Wallis test was used to analyse the pricing trend throughout the 5-year period, and factors that might elevate the MPR above 2.5 were modelled using binary logistic regression. Results A total of 2527 medicine price data were analysed. There was a strong significant association between medicine prices declared to the PSD and the retail medicine prices in every year of the 5-year period. Moreover, there was no significant increase in retail medicine prices throughout the 5-year period. The medicine types, retail location, type of manufacturer, medicinal indications, declared wholesale and RRPs significantly influenced the consumer MPRs that where > 2.5. Conclusion The declared medicine price was found to have a significant association with the consumer retail medicine price. Thus, it may be a useful reference for consumers purchasing medicines in private healthcare settings. However, the government of Malaysia must develop strategies to increase medicine price transparency for price-control mechanisms in the private healthcare sector. Electronic supplementary material The online version of this article (10.1186/s40545-019-0176-z) contains supplementary material, which is available to authorized users.

show abstract

Pharmaceutical Industry in Vietnam: Sluggish Sector in a Growing Market

Cited by 30 publications

References 15 publications

Restructuring the Production of Medicines: An Investigation on the Pharmaceutical Sector in China and the Role of Mergers and Acquisitions

Restructuring the Production of Medicines: An Investigation on the Pharmaceutical Sector in China and the Role of Mergers and Acquisitions

“I can make more from selling medicine when breaking the rules” – understanding the antibiotic supply network in a rural community in Viet Nam

Association between medicine Price declaration by pharmaceutical industries and retail prices in Malaysia’s private healthcare sector

Contact Info

Product

Resources

About